BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.

Abstract accepted at EHA2023 describing the potential for BCL-2 inhibition in adult patients with mature B-cell malignancies.

Abstract accepted at EHA2023 outlining the effectiveness and safety of a BTKi treatment in patients with treatment naïve (TN) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Abstract accepted at EHA2023 describing the assessment of HRQoL in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients treated with 2 different BTKis.

Abstract accepted at EHA2023 outlining the results of a meta-analysis determining the validity of ORR as a surrogate endpoint for PFS and OS, and PFS as a surrogate endpoint for OS in chronic lymphocytic leukemia (CLL).